Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-017252
Filing Date
2025-05-15
Accepted
2025-05-15 17:01:16
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q nrxp20250331c_10q.htm   iXBRL 10-Q 1372035
2 EXHIBIT 10.6 ex_818322.htm EX-10.6 599287
3 EXHIBIT 10.7 ex_818323.htm EX-10.7 586797
4 EXHIBIT 31.1 ex_814422.htm EX-31.1 13131
5 EXHIBIT 31.2 ex_814423.htm EX-31.2 12961
6 EXHIBIT 32.1 ex_814424.htm EX-32.1 5361
7 EXHIBIT 32.2 ex_814425.htm EX-32.2 5117
13 fig1.jpg GRAPHIC 91491
14 fig2.jpg GRAPHIC 60210
  Complete submission text file 0001437749-25-017252.txt   10052944

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250331.xsd EX-101.SCH 75021
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrxp-20250331_cal.xml EX-101.CAL 32150
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250331_def.xml EX-101.DEF 532713
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250331_lab.xml EX-101.LAB 433378
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250331_pre.xml EX-101.PRE 563513
84 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250331c_10q_htm.xml XML 1235972
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 25955135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)